GlassScriptPhysician profile
Maria N Biard
NPI 1073589586
$10,674.53
in general payments reported to CMS, 2019-2025
55 companies · $26.92 in 2025
The $26.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,309 · 2020: $1,304 · 2021: $3,436 · 2022: $2,955 · 2023: $588 · 2024: $55.31 · 2025: $26.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,175.16 | 2019-2023 | Farxiga, Breztri |
| Abbvie INC. | $1,071.17 | 2019-2023 | Ubrelvy, Vraylar, Creon |
| Novo Nordisk INC | $913.57 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $787.19 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $706.62 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $579.28 | 2019-2022 | |
| Pfizer INC. | $571.79 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.59 | 2019-2023 | Jardiance |
| Amgen INC. | $412.93 | 2019-2023 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $395.18 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $346.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $341.09 | 2019-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.30 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $239.49 | 2019-2021 | |
| Allergan, INC. | $209.47 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Biard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.